Brainstorm Cell Therapeutics Stock Forecast, Price & News

+0.05 (+1.44 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume124,485 shs
Average Volume137,224 shs
Market Capitalization$128.21 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BCLI News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Brainstorm Cell Therapeutics logo

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.02 out of 5 stars

Medical Sector

542nd out of 1,349 stocks

Biological Products, Except Diagnostic Industry

82nd out of 193 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Frequently Asked Questions

Is Brainstorm Cell Therapeutics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Brainstorm Cell Therapeutics stock.
View analyst ratings for Brainstorm Cell Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Brainstorm Cell Therapeutics?

Wall Street analysts have given Brainstorm Cell Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Brainstorm Cell Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics saw a increase in short interest during the month of August. As of August 13th, there was short interest totaling 1,040,000 shares, an increase of 16.3% from the July 29th total of 894,200 shares. Based on an average trading volume of 298,600 shares, the short-interest ratio is currently 3.5 days. Approximately 3.5% of the shares of the company are sold short.
View Brainstorm Cell Therapeutics' Short Interest

When is Brainstorm Cell Therapeutics' next earnings date?

Brainstorm Cell Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, October 21st 2021.
View our earnings forecast for Brainstorm Cell Therapeutics

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) issued its quarterly earnings data on Thursday, August, 5th. The biotechnology company reported ($0.17) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.24) by $0.07.
View Brainstorm Cell Therapeutics' earnings history

How has Brainstorm Cell Therapeutics' stock price been impacted by COVID-19?

Brainstorm Cell Therapeutics' stock was trading at $6.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BCLI stock has decreased by 47.2% and is now trading at $3.53.
View which stocks have been most impacted by COVID-19

What price target have analysts set for BCLI?

1 Wall Street analysts have issued 12-month price objectives for Brainstorm Cell Therapeutics' shares. Their forecasts range from $12.00 to $12.00. On average, they anticipate Brainstorm Cell Therapeutics' share price to reach $12.00 in the next year. This suggests a possible upside of 239.9% from the stock's current price.
View analysts' price targets for Brainstorm Cell Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Brainstorm Cell Therapeutics' key executives?

Brainstorm Cell Therapeutics' management team includes the following people:
  • Chaim Lebovits, Chief Executive Officer
  • Ralph Z. Kern, President & Chief Medical Officer
  • David Setboun, Chief Operating Officer & Executive Vice President
  • Preetam Shah, Chief Financial Officer, Treasurer & Executive VP
  • Yael Gothelf, Vice President-Scientific & Regulatory Affairs

Who are some of Brainstorm Cell Therapeutics' key competitors?

What other stocks do shareholders of Brainstorm Cell Therapeutics own?

What is Brainstorm Cell Therapeutics' stock symbol?

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

Who are Brainstorm Cell Therapeutics' major shareholders?

Brainstorm Cell Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.89%), JPMorgan Chase & Co. (1.92%), BlackRock Inc. (1.31%), Susquehanna International Group LLP (0.00%), Millennium Management LLC (1.02%) and Geode Capital Management LLC (0.73%). Company insiders that own Brainstorm Cell Therapeutics stock include David Setboun, International Holdings Ltd Acc, Preetam Shah, Ralph Dr Kern and Sankesh Abbhi.
View institutional ownership trends for Brainstorm Cell Therapeutics

Which major investors are selling Brainstorm Cell Therapeutics stock?

BCLI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Northern Trust Corp, Geode Capital Management LLC, JPMorgan Chase & Co., Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for Brainstorm Cell Therapeutics
or view top insider-selling stocks.

Which major investors are buying Brainstorm Cell Therapeutics stock?

BCLI stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Ergoteles LLC, Simplex Trading LLC, Tibra Equities Europe Ltd, Vanguard Group Inc., Renaissance Technologies LLC, GSA Capital Partners LLP, and Goldman Sachs Group Inc.. Company insiders that have bought Brainstorm Cell Therapeutics stock in the last two years include David Setboun, Preetam Shah, Ralph Dr Kern, and Sankesh Abbhi.
View insider buying and selling activity for Brainstorm Cell Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Brainstorm Cell Therapeutics' stock price today?

One share of BCLI stock can currently be purchased for approximately $3.53.

How much money does Brainstorm Cell Therapeutics make?

Brainstorm Cell Therapeutics has a market capitalization of $128.21 million. The biotechnology company earns $-31,810,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis.

How many employees does Brainstorm Cell Therapeutics have?

Brainstorm Cell Therapeutics employs 40 workers across the globe.

What is Brainstorm Cell Therapeutics' official website?

The official website for Brainstorm Cell Therapeutics is

Where are Brainstorm Cell Therapeutics' headquarters?

Brainstorm Cell Therapeutics is headquartered at 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019.

How can I contact Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at (201) 488-0460 or via email at [email protected].

This page was last updated on 9/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.